Vernalis extends cancer research collaboration with Novartis Institutes for BioMedical Research
09 August 2004
- Joint research and development programme on Hsp90, a target implicated in a number of different cancers
- Vernalis to receive a $1.5 million signature fee
- Novartis to fund future research and development
- Novartis to make an investment in new Vernalis shares of approximately £5 million
- Collaboration validates Vernalis' structure-based drug design capability
Vernalis plc (LSE:VER, Nasdaq: VNLS) today announces that the
Novartis Institutes for BioMedical Research, Inc., (Novartis) has
exercised its option to license exclusive worldwide rights to
Vernalis' lead oncology research programme on Hsp90. Today's
announcement is the positive conclusion of the option agreement the
companies signed in December 2003.
The companies will conduct a joint research programme under which Novartis will provide research funding to Vernalis over an initial three-year period. In addition, Novartis is responsible for funding and conducting the preclinical and clinical development of product candidates, and for commercialisation.
Novartis will pay Vernalis a signature fee of $1.5 million and a series of further payments upon achievement of development milestones for each product candidate that Novartis takes into development. Vernalis will also receive royalties on commercial sales of collaboration products. In addition, Novartis will make an equity investment of approximately £5 million ($9 million) through the subscription for 7,106,344 new Vernalis ordinary shares at 70.18p per share, representing almost 4.6% percent of Vernalis' enlarged issued share capital. The methodology for calculating the subscription price was established at the time of entering the option agreement in December 2003.
In the event that two product candidates from the collaboration reach the market, total payments to Vernalis from Novartis could exceed $75 million, excluding royalties.
The Vernalis Hsp90 programme is the result of a collaboration established in March 2002 with Cancer Research Technology Ltd (CRT) [formerly Cancer Research Ventures Ltd] and The Institute of Cancer Research, under which Vernalis will pay CRT and The Institute of Cancer Research a proportion of its revenues from the agreement with Novartis.
Simon Sturge, chief executive officer of Vernalis said, “I am delighted to be announcing a third major deal for Vernalis in only six weeks. Novartis is a world leader in oncology and an optimal partner to help maximise the opportunity for developing Hsp90 inhibitors as potential cancer treatments. This collaboration further validates Vernalis' research capability and provides additional funding.”
----ends----
Enquiries:
Vernalis plc
Simon Sturge, Chief Executive
Officer
Tony Weir, Chief Financial Officer
+44 (0)118 977 3133
Brunswick Group (for analyst, financial media
enquiries)
Jon Coles; Wendel Carson
+44 (0)20 7404 5959
Safe Harbour statement: this news release may contain forward-looking statements that reflect the Company's current expectations regarding future events, including the clinical development and regulatory clearance of the Company's products, including that of frovatriptan for menstrually-associated migraine, the Company's ability to find partners for the development and commercialisation of its products, including a new commercialisation partner (or partners) for frovatriptan, as well as the terms of such partnership(s), the projected benefits of reacquiring the rights to frovatriptan in North America and/or any new partnership arrangement(s) on the Company's liquidity and results of operations, as well as the Company's working capital requirements and future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the success of the Company's research strategies, the applicability of the discoveries made therein, and the successful and timely completion of clinical studies, including with respect to frovatriptan and the Company's other products, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of frovatriptan and other products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the ability of the Company to obtain additional financing for its operations and the market conditions affecting the availability and terms of such financing, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions and the risks described in our most recent annual report on Form 20-F filed with the U.S. Securities and Exchange Commission (File No 0-20104).
